BioPlayground

PC

ProtocolCore

Suggested Protocols

探索型MVP
すべてのプロトコル分野

Protein & Antibody Workflows — Recombinant Production

製品を一度定義し、科学的に異なる生産 route を選択

protein・antibody・host record ごとに catalog を増やしません。共通 Product Definition から BL21/T7、HEK293 transient、CHO transient、CHO stable pool、CHO clonal producer を選び、選択 route だけを export します。

編集可能な開始プロトコル

5 bounded routes

このプロトコルは何を行いますか？

製品定義を先に固定し、微生物または哺乳類のrouteを一つだけ選択して、培養・発現・回収・精製・QCを同じsourceから接続します。

対応する生産route

  • • G. Recombinant expression, production & purification

適用範囲

HEKとCHO、transientとstable pool・cloneの条件は共有しません。未選択hostの条件を推奨またはexportしません。

Protein Production の保存状態を確認しています。

Research Use Only。製品 release / 規制 lot release ではありません。

PRT-PROTEIN-PRODUCTION-P1D-001G. Recombinant expression, production & purification

Source-Governed Recombinant Protein Production Composer

Protein & Antibody Workflows > Recombinant Protein Expression, Production & Purification · PRT-PROTEIN-PRODUCTION-P1D-CENSUS-20260828

公式ガイド 確認済み
ONE_CATALOG_ENTRY_FIVE_BOUNDED_ROUTESBL21_HEK_CHO_CONDITIONS_NEVER_SHAREDTRANSIENT_POOL_CLONE_TERMINAL_STATES_DISTINCTEXACT_HOST_DERIVATIVE_AND_SOURCE_REQUIREDFIVE_SOURCE_BLOCKS_REQUIREDSOURCE_GOVERNED_COMPOSEDCONNECT_HANDOFF_CONTRACT_REQUIREDADD_REMOVE_REPLACE_FOR_PERSONALIZATIONNO_UNIVERSAL_NUMERIC_DEFAULTSRESEARCH_USE_ONLY

PROTEIN PRODUCTION FOUNDATION

目的と範囲

研究用 recombinant protein production composer です。製品・construct・exact host を記録し、host biology と expression mode が異なる5 route を分離します。GMP、release、臨床・診断適合性、biosafety class は認証しません。

開始前に定義する項目

  • 製品 identity・目的・format・subunit
  • Sequence/construct version と tag・signal・marker
  • 必要な folding・PTM/glycan・assembly・activity
  • Target scale/context と downstream use
  • Exact host derivative・stock/bank・medium/system

実行前確認

  • host family 名だけでなく exact derivative/source を確認
  • host・expression・recovery・purification・quality snapshot を別々に記録
  • route 間で数値条件を carry-over しない
  • manufacturer step 変更を ADD/REMOVE/REPLACE と qualification で記録
  • stop/route-out と terminal state を事前定義

内部 route map

BL21、HEK、CHO を多数の host card にせず、1 composer 内の bounded route とします。CHO stable pool と clonal producer も terminal state が違うため分離します。

BL21(DE3) 系 T7 微生物発現

Transformation/selection、source-qualified seed、small expression screen、induction、total/soluble/localized assessment 後に scale または route-out。

Product/construct definitionExact strain/vector qualificationTransformation and selectionSource-qualified seedSmall expression screenInduction strategyTotal/soluble/localized assessmentScale or route-outHarvest/recoveryPurification/QC handoff

Terminal: Assessed microbial harvest fraction with total/soluble/insoluble or localized-state provenance

HEK293 系 transient 発現

Exact HEK293 derivative、adherent/suspension platform、transfection system、expression/viability、secreted/intracellular harvest を記録。

Product/construct definitionExact HEK derivative/platform qualificationMaintenance/seed readinessTransfection readinessConstruct deliveryExpression/viability monitoringSecreted or intracellular harvestClarificationPurification/QC handoff

Terminal: Assessed HEK293-derived transient harvest with cell/platform and batch provenance

CHO 系 transient 発現

Exact CHO derivative と CHO-specific transfection/protocol variant を使い、HEK 条件を継承しません。

Product/construct definitionExact CHO derivative/platform qualificationMaintenance/seed readinessCHO transfection readinessConstruct delivery and protocol variantExpression/viability monitoringHarvestClarificationPurification/QC handoff

Terminal: Assessed CHO-derived transient harvest with exact protocol-variant and batch provenance

CHO stable pool 開発

Integration/transfection、selection、pool recovery、productivity/product quality/stability を経て qualified stable population で終了。

Product/construct definitionExact CHO platformTransfection/integrationSelectionStable-pool recoveryPool productivity/product-quality screenStability assessmentQualified poolProduction harvestPurification/QC handoff

Terminal: Qualified CHO stable pool with selection, productivity, product-quality, and stability provenance

CHO clonal producer 開発

Stable population から single-cell provenance、clone screening、stability、banking へ進み、clonality を推定しません。

Product/construct definitionExact CHO platformTransfection/integrationSelection and pool recoverySingle-cell isolation/provenanceClone screeningProductivity/product-quality/stabilityQualified bankProduction harvestPurification/QC handoff

Terminal: Qualified CHO clonal producer bank with single-cell provenance, clone selection, stability, and bank record

共通 decision / stop

  • 製品要件と host/route が不適合なら保留
  • starting culture が source readiness を満たさなければ停止
  • expression・solubility・viability・stability・clonality evidence 不足なら route-out
  • recovery output と purification input が不適合なら CONNECT failure
  • QC は fit-for-purpose であり自動 release ではない

最終 handoff

選択 route、exact sources、batch/fraction/QC provenance、全 CONNECT、change ledger、terminal state、storage、未解決 risk を保存します。未選択 host 条件は export しません。

Reference 利用原則

本文は基本 workflow を説明します。実際の reagent・medium・time・temperature・selection・harvest・resin 条件は選択した manufacturer document/revision が支配します。Paper は topology と branch の根拠であり、自動 recipe ではありません。

ADD / REMOVE / REPLACE

Manufacturer protocol を採用する場合も exact product・catalog・lot/bank・document revision・locator を記録します。step/condition の追加・削除・置換には ADD / REMOVE / REPLACE、理由、local qualification、rollback が必須です。

Research Use Only · no GMP, release, clinical/diagnostic-fitness, or biosafety-class claim.

使用前に自分のassay情報を入力してください

実行順序と合理的な開始条件を整理した下書きです。サンプルのprimer・probe配列は含めていません。必ず自分の標的配列を入力し、実際の酵素・kit・装置の説明書とassay検証データに合わせて条件を確定してください。

1

0. DEFINE THE PRODUCT AND INTENDED USE

Record protein or antibody identity, research purpose, format/subunits, sequence and construct version, expected localization, folding/PTM/assembly/activity needs, target scale, downstream use, and fit-for-purpose quality context before selecting a host.

条件: No universal best host is assigned. Unresolved product attributes remain explicit routing questions.
2

1. SELECT ONE BOUNDED PRODUCTION ROUTE

Choose BL21/T7, HEK293 transient, CHO transient, CHO stable pool, or CHO clonal producer. Record the exact strain/cell derivative and expression mode; do not create a protocol card for each protein, antibody, or host record.

条件: Changing route resets route-specific sources, handoffs, and decisions so conditions cannot leak across hosts.
3

2. FREEZE CONSTRUCT AND HOST-SYSTEM RECORDS

Link the product definition to one exact expression construct and one exact host/stock/bank record. Capture vector/promoter, signal/localization elements, tags, markers, multi-chain pairing, host origin, derivative, source, lot/bank/passage context, medium/system, and change history.

試薬: USER REQUIRED — exact construct and host-system records条件: HEK293 derivatives and CHO derivatives are not synonyms; BL21(DE3) is not equivalent to non-DE3 or non-T7 microbial systems.
4

3. QUALIFY THE ROUTE-SPECIFIC STARTING CULTURE

Follow the exact host-system source for transformation/selection and seed preparation in the microbial route, or maintenance/seed readiness in mammalian routes. Stable routes additionally require an integration/selection plan and defined population endpoint.

条件: Record actual readiness evidence and route out when the exact source requirements are not met.
5

4. EXECUTE THE SELECTED EXPRESSION OR DEVELOPMENT ROUTE

Apply only the selected route state machine: small-screen and induction for BL21/T7; transient transfection and monitoring for HEK293 or CHO; integration, selection, pool recovery, and optional clonal development only in the corresponding stable route.

試薬: USER REQUIRED — exact expression/transfection/integration/selection source snapshot条件: All manufacturer additions, removals, or replacements are explicit. The scaler performs arithmetic only from user-entered source values and recommends no reagent or condition.
6

5. PASS ROUTE-SPECIFIC DECISION AND STOP POINTS

Assess total versus soluble/localized expression for BL21, cell/platform readiness and harvest criteria for transient mammalian routes, stable-population qualification for stable pools, and single-cell provenance plus stability/banking evidence for clonal producers.

条件: Low expression, incompatible quality, failed recovery, unsupported clonality, or source mismatch causes hold or route-out rather than an automatic PASS.
7

6. HARVEST, RECOVER, AND PRESERVE FRACTION PROVENANCE

Record harvest criterion, localization, starting matrix, clarification or lysis/refolding/membrane operation, retained and discarded fractions, volume/concentration basis, deviations, and the exact material state handed to purification.

条件: Secreted supernatant, intracellular soluble fraction, inclusion body, periplasmic and membrane fraction are different inputs and never share a hidden recovery recipe.
8

7. DESIGN AND EXECUTE THE SOURCE-GOVERNED PURIFICATION TRAIN

Choose capture, intermediate, and polishing operations only when required by the product and supported by exact product/resin/membrane/equipment IFUs. Record the fraction ledger and every source-to-source CONNECT contract.

試薬: USER REQUIRED — exact purification product and IFU snapshots条件: A general handbook does not authorize resin-specific capacity, flow, buffer, pressure, cleaning, or lifetime values.
9

8. COMPLETE FIT-FOR-PURPOSE PRODUCT QC

Record method and result provenance for quantity, identity, purity/aggregate, activity, product-specific PTM/assembly, process/product impurities and endotoxin context where relevant. Define acceptance in relation to the stated research use.

条件: The composer does not infer release criteria, potency, GMP readiness, clinical suitability, or manufacturing consistency.
10

9. CLOSE THE ROUTE-SPECIFIC HANDOFF

Export only the selected route, exact source snapshots, CONNECT reviews, change ledger, batch/fraction/QC records, terminal state, storage, and downstream handoff. Keep unresolved risks and route-outs visible.

条件: Output is Research Use Only. Stable pool and clonal producer bank remain distinct terminal states.